N6-Substituted N-alkyladenosine-5'-uronamides: bifunctional ligands having recognition groups for A1 and A2 adenosine receptors
- 1 September 1986
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 29 (9) , 1683-1689
- https://doi.org/10.1021/jm00159a020
Abstract
The coronary vasoactivity of N-ethyl-1''-deoxy-1''-(6-amino-9H-purin-9-yl)-.beta.-D-ribofuranuronamide (NECA, 1) is over 2 orders of magnitude greater than that of adenosine and the vasoactivity of certain N6-substituted adenosines is as much as 1 order of magnitude greater. Such results suggest that a combination of appropriate modifications at N6 and C-5'' might additively augment the agonist potency of adenosine. At low temperatures 1-deoxy-1-(6-chloro-9H-purin-9-yl)-2'',3''-O-isopropylidene-.beta.-D-ribofuranosyl chloride (5), obtained in three steps from inosine, reacts with amines to yield uronamides. The subsequent reaction of such uronamides with amines at elevated temperatures displaces the purine 6-chloro group to yield, after deblocking, N-alkyl(or aryl)-N6-alk(ar)yladenosine-5''-uronamides. At the coronary artery A2 receptor the potency of N6-modified analogues of 1 is similar to that of the N6-substituted adenosine, rather than equal to or greater than 1. As agonists in the A2 receptor-mediated stimulation of adenylate cyclase in plasma membranes of PC12 pheochromocytoma cells or human platelets, N6-substituted analogues of 1 are intermediate between the high potency of 1 and the lower potency of the N6-substituted adenosines. At the A1 receptor of rat brain the potency of an N6-substituted analogue of 1 is often greater than that of the corresponding N6-substituted adenosine. At all four receptors, replacing the ethyl group of N-ethyl-N6-3-pentyladenosine-5''-uronamide by larger alkyl groups reduces potency; amides of secondary amines are inactive or have only marginal activity. Analogues of 1 containing a chiral center in the N6 substituent retain the stereoselectivity characteristic of each of the four receptors. Thus, at either A1 or A2 adenosine receptors, adenosine analogues interact with both the N6 and the C-5'' receptor regions. However, the effects of N6 and C-5'' modifications on potency are less than additive, evidence that the interaction of a substituent with its receptor region influences the interaction of other substituents with their respective receptor regions.This publication has 10 references indexed in Scilit:
- Dog coronary artery adenosine receptor. Structure of the N6-aryl subregionJournal of Medicinal Chemistry, 1986
- Functionalized congeners of 1,3-dipropyl-8-phenylxanthine: Potent antagonists for adenosine receptors that modulate membrane adenylate cyclase in pheochromocytoma cells, platelets and fat cellsLife Sciences, 1986
- Dog coronary artery adenosine receptor: structure of the N6-alkyl subregionJournal of Medicinal Chemistry, 1985
- Effects of several 5?-carboxamide derivatives of adenosine on adenosine receptors of human platelets and rat fat cellsNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1984
- LIGAND SELECTIVITY OF DOG CORONARY ADENOSINE RECEPTOR RESEMBLES THAT OF ADENYLATE-CYCLASE STIMULATORY (RA) RECEPTORS1983
- Adenosine receptors in brain membranes: binding of N6-cyclohexyl[3H]adenosine and 1,3-diethyl-8-[3H]phenylxanthine.Proceedings of the National Academy of Sciences, 1980
- Subclasses of external adenosine receptors.Proceedings of the National Academy of Sciences, 1980
- Modification of the 5' position of purine nucleosides. 2. Synthesis and some cardiovascular properties of adenosine-5'-(N-substituted)carboxamidesJournal of Medicinal Chemistry, 1980
- Coronary vasoactivity of adenosine in the conscious dog.Circulation Research, 1979
- Modification of the 5' position of purine nucleosides. 1. Synthesis and biological properties of alkyl adenosine-5'-carboxylatesJournal of Medicinal Chemistry, 1976